Optimus Lifescience Invests 130 Crore in Telangana's API Growth

Optimus Life Science Private Limited is set to make a significant contribution to the pharmaceutical landscape with its upcoming project, the New Active Pharmaceutical Ingredients Unit in Chinnakondoor, Yadadri Bhuvanagiri, Telangana. With a substantial investment of ₹130 Crore, the project focuses on the production of essential Active Pharmaceutical Ingredients (APIs), including Rifaximin (1351.8 TPA) and Dithranol (1.5 TPA). Rifaximin, an antibiotic, is utilized for treating various conditions such as traveler's diarrhea, bacterial overgrowth in the small intestine, and hepatic encephalopathy, while Dithranol serves as a topical medication for psoriasis treatment.

Having already secured the necessary government clearances, construction work is poised to commence soon. The initiative aligns with Optimus Life Science Private Limited's commitment to meeting the increasing demand for APIs in India, contributing to improved access to affordable healthcare.

By creating employment opportunities, enhancing infrastructure, and addressing the rising demand for pharmaceutical ingredients, Optimus Life Science Private Limited's Active Pharmaceutical Ingredients Unit Project stands as a positive development for both the local community and the broader Indian pharmaceutical industry.

News by Rahul Yelligetti